Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Perrone

Showing results (151-160 of 272) with videos related to

Pageof 28
Sort By:
Lung Cancer (Amsterdam, Netherlands)|August 22, 2013
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)M Neil Reaume, Natasha B Leighl, Nicole Mittmann, et al.
Anticancer Research|May 4, 2005
Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancerCecilia Nisticò, Andrea De Matteis, Emanuela Rossi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 23, 2022
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groupsClorinda Schettino, Lucia Musacchio, Michele Bartoletti, et al.
JCO Oncology Practice|January 11, 2024
Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care SystemFrancesco Sparano, Johannes M Giesinger, Gianluca Gaidano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reactionGiuseppe Palmieri, Paolo A Ascierto, Francesco Perrone, et al.
JAMA Network Open|February 23, 2023
Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint InhibitorsDaniel A Goldstein, Gary M Ginsberg, Dorit Hofnung-Gabbay, et al.
BMC Cancer|March 26, 2005
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experienceErmelinda De Maio, Adriano Gravina, Carmen Pacilio, et al.
Critical Reviews in Oncology/Hematology|March 6, 2021
Second medical opinion in oncological settingMarco Maruzzo, Nicla La Verde, Antonio Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Identification of cripto-1 as a novel serologic marker for breast and colon cancerCaterina Bianco, Luigi Strizzi, Mario Mancino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient dataAntonio Rossi, Massimo Di Maio, Paolo Chiodini, et al.
Pageof 28

Showing results (151-160 of 272) with videos related to

Sort By:
Pageof 28
Lung Cancer (Amsterdam, Netherlands)|August 22, 2013
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)M Neil Reaume, Natasha B Leighl, Nicole Mittmann, et al.
Anticancer Research|May 4, 2005
Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancerCecilia Nisticò, Andrea De Matteis, Emanuela Rossi, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 23, 2022
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groupsClorinda Schettino, Lucia Musacchio, Michele Bartoletti, et al.
JCO Oncology Practice|January 11, 2024
Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care SystemFrancesco Sparano, Johannes M Giesinger, Gianluca Gaidano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reactionGiuseppe Palmieri, Paolo A Ascierto, Francesco Perrone, et al.
JAMA Network Open|February 23, 2023
Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint InhibitorsDaniel A Goldstein, Gary M Ginsberg, Dorit Hofnung-Gabbay, et al.
BMC Cancer|March 26, 2005
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experienceErmelinda De Maio, Adriano Gravina, Carmen Pacilio, et al.
Critical Reviews in Oncology/Hematology|March 6, 2021
Second medical opinion in oncological settingMarco Maruzzo, Nicla La Verde, Antonio Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Identification of cripto-1 as a novel serologic marker for breast and colon cancerCaterina Bianco, Luigi Strizzi, Mario Mancino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient dataAntonio Rossi, Massimo Di Maio, Paolo Chiodini, et al.
Pageof 28